Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients

Yuanyuan Sun, Ling Li, Xin Li, Lei Zhang, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jingjing Wu, Hui Yu, Yu Chang, Jiaqin Yan, Xiaolong Wu, Zhiyuan Zhou, Feifei Nan, Li Tian, Mingzhi Zhang, Yuanyuan Sun, Ling Li, Xin Li, Lei Zhang, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jingjing Wu, Hui Yu, Yu Chang, Jiaqin Yan, Xiaolong Wu, Zhiyuan Zhou, Feifei Nan, Li Tian, Mingzhi Zhang

Abstract

Aim: To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma).

Methods: An open-label prospective clinical trial with 153 newly diagnosed PTCL patients conducted between January 2010 and December 2018 was designed. Patients were randomly assigned to the GDPT (77 cases) and CHOP (76 cases) groups. Patients in each group were further divided into four subgroups: PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma (AITL), and other types subgroup, in accordance with pathological patterns. Based on expression of RRM1, TOP2A, TUBB3, and ERCC1, patients were divided into groups with high and low gene expression levels. Clinical characteristics, side effects, efficacy, progression-free survival (PFS), and overall survival (OS) were compared.

Results: There were no significant differences in the basic clinical features or side effects between the GDPT and CHOP groups. The overall response rate (ORR) of the GDPT group was better than that of the CHOP group (66.3% versus 50.0%, p = 0.042), as was the complete remission (CR) rate (42.9% versus 27.6%, p = 0.049). Patients in the GDPT group had a longer PFS and OS than the CHOP group. The 4-year PFS and OS rates in the GDPT group were both superior to those in the CHOP group (63.6% versus 53.0% for PFS, p = 0.035; 66.8% versus 53.6% for OS, p = 0.039). In the GDPT group, the difference in CR between the four subgroups was statistically significant (p = 0.046). In the CHOP group, differences in both CR and ORR among the four subgroups were statistically significant (p < 0.001 and p = 0.005, respectively). There were also statistically significant differences in CR between patients treated with CHOP and GDPT in the PTCL-NOS subgroup, AITL subgroup, and the other types subgroup (p = 0.015; p = 0.003; p = 0.005, respectively). The data also showed a significant difference in OS among the four subgroups within the GDPT group (p = 0.001). The OS of AITL was shorter than that of the other three subgroups. Four subgroups of CHOP showed a significant difference in PFS (p = 0.019). There was no statistical association between responses and the gene expression levels of RRM1, ERCC1, TUBB3, and TOP2A.

Conclusion: The GDPT group had better response rates and prolonged patient PFS and OS. As a promising new regimen, GDPT is expected to become the first-line therapy for PTCL. New agents should be applied to patients who do not achieve good responses with previous treatment, such as those diagnosed with angioimmunoblastic T cell lymphoma.

Trial registration: This open randomized prospective clinical trial was registered at ClinicalTrials.gov (NCT01664975).

Keywords: CHOP; GDPT; genes; outcomes; peripheral T cell lymphoma.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

© The Author(s), 2020.

Figures

Figure 1.
Figure 1.
(A) PFS is shown for all patients; the GDPT group has a better PFS than the CHOP group (p = 0.035). (B) OS is shown for all patients; the GDPT group has a better OS than the CHOP group (p = 0.039). CHOP, cyclophosphamide, vincristine, doxorubicin, prednisone; GDPT, gemcitabine, cisplatin, prednisone, thalidomide; OS, overall survival; PFS, progression-free survival.
Figure 2.
Figure 2.
(A) PFS is shown for patients treated with GDPT, showing no significant difference between the four subgroups (p = 0.357). (B) OS is shown for patients treated with GDPT, showing significant difference between the four subgroups (p = 0.001). CHOP, cyclophosphamide, vincristine, doxorubicin, prednisone; GDPT, gemcitabine, cisplatin, prednisone, thalidomide; OS, overall survival; PFS, progression-free survival.
Figure 3.
Figure 3.
(A) PFS is shown for patients treated with CHOP, showing significant difference between the four subgroups (p = 0.0197). (B) OS is shown for patients treated with CHOP, showing no significant difference between the four subgroups (p = 0.066). CHOP, cyclophosphamide, vincristine, doxorubicin, prednisone; GDPT, gemcitabine, cisplatin, prednisone, thalidomide; OS, overall survival; PFS, progression-free survival.

References

    1. Armitage JO. Peripheral T-cell lymphomas: their time has come. Oncology 2009; 23: 1151–1152.
    1. Dunleavy K, Piekarz RL, Zain J, et al. New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res 2010; 16: 5608–5617.
    1. Patel M. Peripheral T cell lymphoma. Indian J Med Res 2018; 147: 439–441.
    1. Abouyabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011; 2011: 623924.
    1. Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014; 124: 1570–1577.
    1. Bachy E, Coiffier B. Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one? Lancet Haematol 2015; 2: e307–e308.
    1. Park BB, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 2015; 94: 1845–1851.
    1. Qi F, Dong M, He X, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. Ann Hematol 2017; 96: 245–251.
    1. Liu K, Tian H, Zhang Y, et al. miR-451 selectively increases sensitivity to cisplatin in ERCC1-high non-small cell lung cancer cells. J Cell Biochem. Epub ahead of print 6 January 2018. DOI: 10.1002/jcb.26657.
    1. Mlak R, Krawczyk P, Ciesielka M, et al. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. Clin Transl Oncol 2016; 18: 915–924.
    1. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs does TUBB3 work. Curr Cancer Drug Targets 2007; 7: 704–712.
    1. Bartlett JM, McConkey CC, Munro AF, et al. Predicting anthracycline benefit: TOP2A and CEP17-not only but also. J Clin Oncol 2015; 33: 1680–1687.
    1. Asano N, Kato S, Nakamura S. Epstein-Barr virus-associated natural killer/T-cell lymphomas. Best Pract Res Clin Haematol 2013; 26: 15–21.
    1. Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise speci fied. Blood 2017; 129: 1103–1112.
    1. Hapgood G, Savage KJ. Challenges and future directions in peripheral T-cell lymphoma. Hematol Oncol 2015; 33(Suppl. 1): 56–61.
    1. Abouyabis AN, Shenoy PJ, Lechowicz MJ, et al. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008; 49: 2099–2107.
    1. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418–3425.
    1. Chen Y, Li L, Zeng J, et al. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Chemotherapy 2012; 58: 264–272.
    1. Wang Y, Li H, Ma S, et al. Significance of P-glucoprotein, glutathione S-transferase π, topoisomerase II, expression in nodal peripheral T-cell lymphama. Mod Oncol 2009; 17: 1543.
    1. Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk 2014; 14: 335–342.
    1. Kaira K, Yanagitani N, Sunaga N, et al. Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. Oncol Lett 2017; 14: 1123–1128.
    1. Zhou Z, Li X, Chen C, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol 2014; 93: 1889–1894.
    1. Dong M, He XH, Liu P, et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 2013; 30: 351.
    1. Zhang L, Li S, Jia S, et al. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK) T-cell lymphoma, nasal type. Oncotarget 2016; 7: 58396–58404.
    1. Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res 2016; 22: 5223–5228.
    1. Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003; 88: 1963–1970.
    1. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847–857.
    1. Hess LM, Benham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007; 17: 561–570.
    1. Besancon OG, Tytgat GA, Meinsma R, et al. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. Cancer Lett 2012; 319: 23–30.
    1. Huang Y, de Leval L, Gaulard P. Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pract Res Clin Haematol 2013; 26: 57–74.
    1. Martinez-Delgado B, Meléndez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 2004; 10: 4971–4982.
    1. Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012; 48: 3223–3231.
    1. Huang YT, Cheng CC, Chiu TH, et al. Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. Int J Oncol 2015; 47: 1711–1724.
    1. Li L, Duan W, Zhang L, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol 2017; 178: 772–780.
    1. Jinyue F, Shuye W. Analysis of therapy and prognostic factors of chidamide in the treatment of peripheral T-cell lymphoma. J Clin Hematol 2018; 31: 531–534.
    1. Yabe M, Dogan A, Horwitz SM, et al. Angioimmunoblastic T-cell lymphoma. Cancer Treat Res 2019; 176: 99–126.
    1. Dodero A, Maura F, Pellegrinelli A, et al. GATA-3 expression in peripheral T-cell lymphomas (PTCL): identification of a cut-off and prognostic value in PTCL-NOS versus others hystotypes. Blood 2015; 126: 3889.
    1. Khan N, Ozkaya N, Moskowitz A, et al. Peripheral T-cell lymphoma - are we making progress? Best Pract Res Clin Haematol 2018; 31: 306–314.
    1. Ma H, Davarifar A, Amengual JE. The future of combination therapies for peripheral T cell lymphoma (PTCL). Curr Hematol Malig Rep 2018; 13: 13–24.
    1. Amengual JE, Lichtenstein R, Rojas C, et al. Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): the pralatrexate/romidepsin doublet. J Clin Oncol 2016; 34(Suppl.): 2552.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel